EGFR and non-small cell lung carcinoma: Erlotinib and gefitinib, for example, have significantly expanded the therapeutic landscape by specifically targeting mutations of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) [91,92].